Altimmune, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jerome B. Durso
- Full Time Employees
- 57
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 910 Clopper Road Gaithersburg MD United States 20878
- IPO Date
- Oct 6, 2005
- CIK
- 0001326190
- Website
- altimmune.com
- Similar Companies
- Business
- Altimmune, Inc. is a biopharmaceutical company in the late clinical stage, dedicated to developing innovative peptide-based therapies for liver and cardiometabolic conditions. The company's main therapeutic candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing evaluation for several indications, including obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Regarding pemvidutide's progress, the IMPACT Phase 2b MASH trial has completed enrollment, with 24-week data already published in The Lancet and 48-week data anticipated by the end of 2025. An End-of-Phase 2 meeting with the FDA is scheduled for late 2025, with plans to initiate Phase 3 trials in 2026. Pemvidutide has received Fast Track designation from the U.S. FDA for MASH and AUD. Furthermore, Phase 2 trials for AUD (RECLAIM study) and ALD (RESTORE study) are actively enrolling or have completed enrollment. Previously, Altimmune was developing HepTcell, an immunotherapeutic for chronic hepatitis B. However, the company discontinued its development in March 2024 following Phase 2 trial results that were deemed insufficient to warrant further advancement. The company focuses entirely on advancing pemvidutide through clinical development. Altimmune, Inc. maintains its headquarters in Gaithersburg, Maryland.
Company News
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets
Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Altimmune to Participate in Stifel Cardiometabolic Forum
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT)
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Alpha Liquid Terminal Relaunches as the ALT/X Compute Terminal, Pivoting to GPU Pricing, Power and AI Infrastructure Market Data